Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.61 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19487245 | 0.91 | LMNA (0.77) | LMNASMN1; SMN2PDE7APDE7BPDE4A | |
| SCHEMBL1101909 | 0.87 | LMNA (0.72) | LMNASMN1; SMN2PDE7APDE7BPDE4A | |
| SCHEMBL1101917 | 0.87 | LMNA (0.72) | LMNASMN1; SMN2PDE7APDE7BPDE4A | |
| SCHEMBL5030398 | 0.85 | MAPT (0.67) | LMNASMN1; SMN2PDE7APDE7BPDE4A | |
| SCHEMBL2631381 | 0.82 | MAPK1 (0.74) | LMNASMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL5028783 | 0.79 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL28367595 | 0.79 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL29175098 | 0.79 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL28324629 | 0.79 | ALDH1A1 (0.84) | LMNASMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL9671260 | 0.79 | PDE7A (0.84) | SMN1; SMN2PDE7AALDH1A1NPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | LMNA 1374/4885SMN1; SMN2 524/4885PDE7A 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.